MENU

Phillip Abbosh, MD, PhD

Phillip Abbosh, MD, PhD
About

Research Program

Social Media

Twitter: @scientistatlrge

Education, Training & Credentials

Educational Background

  • Urologic Oncology Fellowship, Fox Chase Cancer Center, Philadelphia, PA, 2015
  • Urology Residency, Barnes-Jewish Hospital/Washington University School of Medicine in St. Louis, MO. 2013
  • MD, Indiana University School of Medicine, 2008
  • PhD, Cellular and Integrative Physiology: Indiana University Medical Sciences Program, Bloomington, IN, 2005
  • BS, Biochemistry, Indiana University, Bloomington, IN, 1999

Certifications

  • Pennsylvania Medical License MD449537
  • DEA: FA4049537

Memberships

  • American Association for Cancer Research
  • American Society of Clinical Oncology
  • American Urological Association
  • Society for Urologic Oncology
Research Profile

Research Program

Research Interests

Role of PBRM1 loss in clear cell renal carcinoma

Molecular correlates to complete response to neoadjuvant chemotherapy in bladder cancer

Animal models of bladder cancer using multiplex genome editing

Lab Overview

PBRM1 is the second most commonly mutated gene in clear cell renal cell carcinoma (the most common type of kidney cancer) and was first identified in 2011.  Despite this, little is known about what the role of PBRM1 loss is in kidney cancer.  We are currently exploring changes in chromatin modification that occur after it is lost and identifying potential avenues for personalized treatment strategies in advance cases of kidney cancer.

When patients have muscle-invasive bladder cancer, the standard of care is to be treated with cisplatin-based chemotherapy before surgery to remove the entire bladder. At the time of bladder removal, about 30-40% of patients will not have residual cancer left in their bladder.  Patients and doctors alike wonder if bladder removal is necessary if there is no tumor left.  The answer at this point in time is “yes” because we do not have a way to reliably identify patients who will respond to chemotherapy (prospectively), or patients who actually did respond to chemotherapy (retrospectively).  We are currently using next generation sequencing to prospectively and retrospectively identify responders, with the aim to safely avoid bladder removal in responders in the future.

Lastly, bladder cancer sequencing efforts have revealed a large number of potentially therapeutically tractable targets, but how to target them is still unknown.  These genetic alterations can be modeled in mice using the exciting new genome editing tool CRISPR.  Using this technology, we are making many new bladder cancer models by introducing combinations of mutations into the mouse bladder to try to model the human disease more accurately in mice. This will hopefully allow us to marry individual mutations to therapeutic strategies in anticipation of personalized medicine algorithms in humans.

People

Rahmat Sikder

Scientific Technician

Room: P2119
Publications

Selected Publications

This Fox Chase professor participates in the Undergraduate Summer Research Fellowship
Learn more about Research Volunteering.